{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:18:22Z","timestamp":1787663902045,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd006019","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T00:00:00Z","timestamp":1161129600000}}],"reference-count":110,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006019.pub2","type":"journal-article","created":{"date-parts":[[2006,10,20]],"date-time":"2006-10-20T00:02:14Z","timestamp":1161302534000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer"],"prefix":"10.1002","volume":"2010","author":[{"given":"Satish","family":"Kumar","sequence":"first","affiliation":[{"name":"Singleton Hospital; Department of Oncology; Sketty Lane Swansea Wales UK SA2 8QA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Shelley","sequence":"additional","affiliation":[{"name":"Velindre NHS Trust; Cochrane Prostatic Diseases and Urological Cancers Unit, Research Dept; Velindre Road Whitchurch Cardiff Wales UK CF4 7XL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Harrison","sequence":"additional","affiliation":[{"name":"Velindre NHS Trust; Cardiff Wales UK CF14 2TL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Coles","sequence":"additional","affiliation":[{"name":"Cardiff University; Cancer Research Wales Library; Velindre Cancer Centre Whitchurch Cardiff UK CF14 2TL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Wilt","sequence":"additional","affiliation":[{"name":"VAMC; General Internal Medicine (111-0); One Veterans Drive Minneapolis Minnesota USA 55417"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Mason","sequence":"additional","affiliation":[{"name":"Velindre Hospital; Clinical Oncology; Whitchurch Cardiff UK CF4 7XL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,18]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000473789","article-title":"The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment","volume":"29","author":"Hugosson","year":"1996","journal-title":"European Urology"},{"issue":"9327","key":"10.1002\/14651858.CD006019.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijrobp.2004.02.022","article-title":"Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer","volume":"60","author":"Crook","year":"2004","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0022-5347(01)66266-9","article-title":"Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer","volume":"155","author":"Dalkin","year":"1996","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(05)70348-X","article-title":"Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial","volume":"6","author":"Denham","year":"2005","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","article-title":"Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects","volume":"166","author":"Gleave","year":"2001","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/01.ju.0000081404.98273.fd","article-title":"Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy","volume":"170","author":"Klotz","year":"2003","journal-title":"Journal of Urology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD006019.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(97)00170-2","article-title":"Neoadjuvant hormonal therapy: The Canadian experience","volume":"49","author":"Labrie","year":"1997","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0167-8140(03)00193-2","article-title":"Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer","volume":"68","author":"Lamb","year":"2003","journal-title":"Radiotherapy and Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.ju.0000112979.97941.7f","article-title":"The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer","volume":"171","author":"Laverdiere","year":"2004","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","article-title":"Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer","volume":"97","author":"McLeod","year":"2005","journal-title":"British Journal Urology International"},{"issue":"24","key":"10.1002\/14651858.CD006019.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.[see comment]","volume":"341","author":"Messing","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0360-3016(01)01579-6","article-title":"Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate","volume":"50","author":"Pilepich","year":"2001","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000077113","article-title":"Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: A randomized study","volume":"72","author":"Prezioso","year":"2004","journal-title":"Urologia Internationalis"},{"issue":"6","key":"10.1002\/14651858.CD006019.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1159\/000020366","article-title":"4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer","volume":"38","author":"Schulman","year":"2000","journal-title":"European Urology"},{"issue":"7","key":"10.1002\/14651858.CD006019.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/jcp.55.7.508","article-title":"Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer","volume":"55","author":"Selli","year":"2002","journal-title":"Journal of Clinical Pathology"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0022-5347(05)65393-1","article-title":"Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results","volume":"167","author":"Soloway","year":"2002","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2005.06.005","article-title":"Bicalutamide ('Casodex') 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme","volume":"76","author":"Tyrrel","year":"2005","journal-title":"Radiotherapy and Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0090-4295(98)00542-1","article-title":"Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: Three versus six months of endocrine therapy","volume":"53","author":"Kwast","year":"1999","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2003.10.013","article-title":"Prospective Randomized Trial Comparing Flutamide as Adjuvant Treatment versus Observation after Radical Prostatectomy for Locally Advanced, Lymph Node-Negative Prostate Cancer","volume":"45","author":"Wirth","year":"2004","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD006019.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0360-3016(88)90383-5","article-title":"Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long-term results of a prospective randomized study","volume":"14","author":"Zagars","year":"1988","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0090-4295(99)00107-7","article-title":"Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy","volume":"54","author":"Ahlgren","year":"1999","journal-title":"Urology"},{"issue":"6","key":"10.1002\/14651858.CD006019.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0090-4295(00)00838-4","article-title":"Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume","volume":"56","author":"Ahlgren","year":"2000","journal-title":"Urology"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<274::AID-PROS4>3.0.CO;2-R","article-title":"Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment","volume":"42","author":"Ahlgren","year":"2000","journal-title":"Prostate"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0090-4295(99)00106-5","article-title":"Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities","volume":"54","author":"Akakura","year":"1999","journal-title":"Urology"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1464-410X.2003.04014.x","article-title":"A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up","volume":"91","author":"Akaza","year":"2003","journal-title":"BJU International"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/jjco\/hyh001","article-title":"Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients","volume":"34","author":"Akaza","year":"2004","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0360-3016(97)00388-X","article-title":"Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation","volume":"39","author":"Anderson","year":"1997","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0090-4295(98)00184-8","article-title":"Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study","volume":"52","author":"Andriole","year":"1998","journal-title":"Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0167-8140(04)82038-3","article-title":"Preliminary results of a randomised trial comparing short vs. protracted neoadjuvant hormonal therapy (NHT) prior to radiation therapy (RT) of localized prostate cancer. (Irish Clinical Oncology Research Group Protocol # 97-01)","volume":"73","author":"Armstrong","year":"2004","journal-title":"Radiotherapy and Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<243::AID-PROS5>3.0.CO;2-C","article-title":"Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy","volume":"29","author":"Asbell","year":"1996","journal-title":"Prostate"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000475337","article-title":"Effects of 3 months' neoadjuvant hormonal treatment with a GnRH analogue (triptorelin) prior to radical retropubic prostatectomy on prostate-specific antigen and tumour volume in prostate cancer","volume":"26","author":"Aus","year":"1994","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0035|cit35","first-page":"23-5; discussio","article-title":"Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer","volume":"35 Suppl 1","author":"Bolla","year":"1999","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0022-5347(01)62399-1","article-title":"Neoadjuvant androgen ablation for localized prostatic cancer: Pathology methods, surgical end points and meta-analysis of randomized trials","volume":"160","author":"Bonney","year":"1998","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0090-4295(00)00866-9","article-title":"Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: Progress pathology report of the Italian PROSIT study","volume":"57","author":"Bono","year":"2001","journal-title":"Urology"},{"issue":"11","key":"10.1002\/14651858.CD006019.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00000478-200211000-00002","article-title":"Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: A detailed analysis of radical prostatectomy specimens from a randomized trial","volume":"26","author":"Bullock","year":"2002","journal-title":"American Journal of Surgical Pathology"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<407::AID-CNCR23>3.0.CO;2-0","article-title":"Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues","volume":"88","author":"Chang","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1464-410X.1997.00022.x","article-title":"Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study","volume":"79","author":"Cookson","year":"1997","journal-title":"British Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD006019.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.292.7.821","article-title":"6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial","volume":"292","author":"D'Amico","year":"2004","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3816\/CGC.2002.n.018","article-title":"Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial","volume":"1","author":"Leval","year":"2002","journal-title":"Clinical Prostate Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006019.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000475423","article-title":"A multicentue trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomyin prostate cancer","volume":"26","author":"Debruyne","year":"1994","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0044|cit44","first-page":"251","article-title":"Neoadjuvant hormonal therapy prior to radical prostatectomy: The European experience","volume":"4","author":"Debruyne","year":"2000","journal-title":"Molecular Urology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1464-410X.1992.tb15736.x","article-title":"Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer","volume":"70","author":"Fellows","year":"1992","journal-title":"British Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2003.08.003","article-title":"Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer","volume":"58","author":"Galalae","year":"2004","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0022-5347(01)65645-3","article-title":"Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. [see comment]","volume":"156","author":"Goldenberg","year":"1996","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD006019.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/S0022-5347(01)63235-X","article-title":"Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study","volume":"159","author":"Granfors","year":"1998","journal-title":"Journal of Urology"},{"issue":"21","key":"10.1002\/14651858.CD006019.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02","volume":"21","author":"Hanks","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"229-37; discuss","DOI":"10.1046\/j.1442-2042.1999.00050.x","article-title":"Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group","volume":"6","author":"Homma","year":"1999","journal-title":"International Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1442-2042.2003.00781.x","article-title":"Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer","volume":"11","author":"Homma","year":"2004","journal-title":"International Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0360-3016(00)01443-7","article-title":"Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy","volume":"49","author":"Horwitz","year":"2001","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000473789","article-title":"The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment","volume":"29","author":"Hugosson","year":"1996","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0054|cit54","first-page":"218","article-title":"A prospective randomized trial for treating stages B2 and C prostate cancer: radical surgery or irradiation with neoadjuvant endocrine therapy","volume":"24","author":"Isaka","year":"1994","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0302-2838(02)00311-1","article-title":"A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer first report from the Scandinavian Prostatic Cancer Group Study no. 6","volume":"42","author":"Iversen","year":"2002","journal-title":"European Urology"},{"issue":"5 pt 1","key":"10.1002\/14651858.CD006019.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/01.ju.0000139719.99825.54","article-title":"Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-Year median followup from the Scandinavian Prostate Cancer Group Study Number 6","volume":"172","author":"Iversen","year":"2004","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.urology.2004.02.011","article-title":"Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program","volume":"63","author":"Iversen","year":"2004","journal-title":"Urology"},{"issue":"11","key":"10.1002\/14651858.CD006019.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/cncr.11804","article-title":"Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis","volume":"98","author":"Jani","year":"2003","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0090-4295(98)00616-5","article-title":"CUOG randomised trial of neo-adjuvant androgen ablation before radical prostatectomy: 36 month post treatment PSA results","volume":"53","author":"Klotz","year":"1999","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0060|cit60","first-page":"233","article-title":"Neoadjuvant hormone therapy: The Canadian trials","volume":"4","author":"Klotz","year":"2000","journal-title":"Molecular Urology"},{"issue":"6","key":"10.1002\/14651858.CD006019.pub2-BIB0061|cit61","first-page":"499","article-title":"Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial","volume":"16","author":"Labrie","year":"1993","journal-title":"Clinical and Investigative Medicine. Medecine Clinique et Experimentale"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD006019.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/1097-0142(19930201)71:3+<1059::AID-CNCR2820711426>3.0.CO;2-6","article-title":"Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy","volume":"71","author":"Labrie","year":"1993","journal-title":"Cancer"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD006019.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0090-4295(94)80241-6","article-title":"Down-staging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist","volume":"44","author":"Labrie","year":"1994","journal-title":"Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0064|cit64","first-page":"149","article-title":"Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy","volume":"23","author":"Labrie","year":"1995","journal-title":"Cancer Surveys"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0360-3016(97)00288-5","article-title":"Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31)","volume":"38","author":"Lawton","year":"1997","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0360-3016(00)01516-9","article-title":"Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate","volume":"49","author":"Lawton","year":"2001","journal-title":"International Journal of Radiation, Oncology, Biology, Physics"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31","volume":"23","author":"Lawton","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0360-3016(01)02598-6","article-title":"Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation","volume":"52","author":"Lee","year":"2002","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0069|cit69","first-page":"21","article-title":"The combined treatment of patients with locally disseminated prostatic cancer","volume":"4","author":"Matveev","year":"1993","journal-title":"Urologiia i Nefrologiia"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0070|cit70","first-page":"3599","article-title":"Surgical pathology examination of radical prostatectomy specimens. Updated protocol based on the Italian TAP study","volume":"21","author":"Mazzucchelli","year":"2001","journal-title":"Anticancer Research"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0344-0338(99)80036-3","article-title":"Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study","volume":"195","author":"Montironi","year":"1999","journal-title":"Pathology, Research and Practice"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0360-3016(89)90500-2","article-title":"Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: Preliminary results of RTOG 83-07","volume":"16","author":"Pilepich","year":"1989","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"S1","key":"10.1002\/14651858.CD006019.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0360-3016(93)90822-D","article-title":"Phase III trial of hormone cytoreduction in conjunction with definative radiotherapy in loacally advanced prostate carcinoma: the emerging role of PSA in the assessment of outcome. abstract no: 193","volume":"27","author":"Pilepich","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0360-3016(95)00536-8","article-title":"Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: Outcome results of RTOG 83-07","volume":"32","author":"Pilepich","year":"1995","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0090-4295(99)80053-3","article-title":"Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group","volume":"45","author":"Pilepich","year":"1995","journal-title":"Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1997.15.3.1013","article-title":"Phase III trial of androgen suppression using goserelin in unfavourable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG protocol 85 -31","volume":"15","author":"Pilepich","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006019.pub2-BIB0077|cit77","first-page":"17-21; discussi","article-title":"Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group","volume":"35","author":"Prezioso","year":"1999","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0022-5347(01)63772-8","article-title":"Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group. [see comment]","volume":"159","author":"Rabbani","year":"1998","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0022-5347(01)63574-2","article-title":"Incidence and clinical significance of false-negative sextant prostate biopsies","volume":"159","author":"Rabbani","year":"1998","journal-title":"Journal of Urology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD006019.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/1097-0142(19930201)71:3+<1005::AID-CNCR2820711418>3.0.CO;2-I","article-title":"Adjuvant therapy for localized prostate cancer","volume":"71","author":"Schmidt","year":"1993","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000473791","article-title":"Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation","volume":"29","author":"Schmidt","year":"1996","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1097-0045(199601)28:1<51::AID-PROS7>3.0.CO;2-R","article-title":"Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project","volume":"28","author":"Schmidt","year":"1996","journal-title":"Prostate"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-5347(05)64652-6","article-title":"Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program","volume":"168","author":"See","year":"2002","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0302-2838(03)00366-X","article-title":"Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer","volume":"44","author":"See","year":"2003","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD006019.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0360-3016(02)03052-3","article-title":"Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10","volume":"54","author":"Shipley","year":"2002","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"6","key":"10.1002\/14651858.CD006019.pub2-BIB0086|cit86","first-page":"532","article-title":"Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy","volume":"16","author":"Solomon","year":"1993","journal-title":"Clinical and Investigative Medicine. Medecine Clinique et Experimentale"},{"issue":"2 I","key":"10.1002\/14651858.CD006019.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00005392-199508000-00026","article-title":"Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer","volume":"154","author":"Soloway","year":"1995","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00000478-199601000-00010","article-title":"Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: A randomized study","volume":"20","author":"Vaillancourt","year":"1996","journal-title":"American Journal of Surgical Pathology"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0089|cit89","first-page":"73","article-title":"Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy","volume":"60","author":"Poppel","year":"1992","journal-title":"Acta Urologica Belgica"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD006019.pub2-BIB0090|cit90","first-page":"429","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group","volume":"154","author":"Poppel","year":"1995","journal-title":"Journal of Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006019.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000052544","article-title":"Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out","volume":"39","author":"Poppel","year":"2001","journal-title":"European Urology"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD006019.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1097\/01.ju.0000140159.94703.80","article-title":"Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years","volume":"172","author":"Wirth","year":"2004","journal-title":"Journal of Urology"},{"issue":"Suppl 3A","key":"10.1002\/14651858.CD006019.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0090-4295(97)00171-4","article-title":"Preliminary results of a prospective randomised study comparing radical prostatectomy versus radical prostatectomy associated with neo-adjuvant hormonal combination therapy in T2-3N0M0 prostatic carcinoma","volume":"49","author":"Witjes","year":"1997","journal-title":"Urology"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/pros.20171","article-title":"Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer","volume":"63","author":"Yamanaka","year":"2005","journal-title":"Prostate"},{"issue":"4","key":"10.1002\/14651858.CD006019.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0360-3016(99)00089-9","article-title":"Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX\/N0, M0) adenocarcinoma of the prostate","volume":"44","author":"Zagars","year":"1999","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"2","key":"10.1002\/14651858.CD006019.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0302-2838(02)00257-9","article-title":"Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863","volume":"42","author":"Zurlo","year":"2002","journal-title":"European Urology"},{"issue":"Suppl","key":"10.1002\/14651858.CD006019.pub2-BIB0097|cit97","first-page":"393","article-title":"Pretreatment with triptorelin before radical prostatectomy: a 3 year follow up","volume":"158","author":"Aus","year":"1997","journal-title":"Journal of Urology"},{"issue":"Suppl","key":"10.1002\/14651858.CD006019.pub2-BIB0098|cit98","first-page":"61","article-title":"Neo-adjuvant treatment before radical prostatectomy decreases the number of positive margins in CT2-T3 but has no impact on PSA progression or survival in CT2-T3","volume":"159","author":"Baert","year":"1998","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0360-3016(00)80021-8","article-title":"RTOG protocol 9202: a phase 111 trial of the use of long term androgen suppression following neo adjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate","volume":"48","author":"Hanks","year":"2000","journal-title":"International Journal of Radiation Oncology Biology and Physics"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0101|cit101","first-page":"293","article-title":"Studies on prostate cancer 1: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD006019.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"3","key":"10.1002\/14651858.CD006019.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ijrobp.2005.03.010","article-title":"Ecomomic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10)","volume":"63","author":"Konski","year":"2005","journal-title":"International Journal Radiation Oncology Biology and Physics"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.21575","article-title":"Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate cancer","volume":"106","author":"Konski","year":"2006","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0360-3016(96)00513-5","article-title":"Beneficial effect of combination hormonal therapy administered prior and following external beam irradiation in localised prostate cancer","volume":"37","author":"Laverdiere","year":"1997","journal-title":"International Journal of Radiation Oncology Biology and Physics"},{"issue":"3, suppl 1","key":"10.1002\/14651858.CD006019.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/suro.2002.35055","article-title":"Neoadjuvant Strategies for Prostate Cancer Prior Radical Prostatectomy","volume":"20","author":"Meng","year":"2002","journal-title":"Seminars in Urological Oncology"},{"issue":"12","key":"10.1002\/14651858.CD006019.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3120","article-title":"Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.","volume":"3","author":"Moher","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD006019.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0360-3016(00)80131-5","article-title":"Androgen ablation adjuvant to definitive radiotherapy in carcinoma of the prostate: year 2000 update of RTOG phase 111 studies 86-10 and 85-31","volume":"48","author":"Pilepich","year":"2000","journal-title":"International Journal Radiation Oncology Biology Physics"},{"issue":"May - June (3)","key":"10.1002\/14651858.CD006019.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1078-1439(02)00242-9","article-title":"A cost-outcome analysis of long-term adjuvant gorserelin in addition to radiotherapy for locally advanced prostate cancer","volume":"21","author":"Samant","year":"2003","journal-title":"Urological Oncology"},{"key":"10.1002\/14651858.CD006019.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0022-5347(05)68574-6","article-title":"Prostate brachytherapy: treatment strategies","volume":"162","author":"Stone","year":"1999","journal-title":"Journal of Urology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006019.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:20:26Z","timestamp":1787660426000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006019.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2006,10,18]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006019.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,18]]}}}